(Q42245027)

19 October 2017

0 references

Successful treatment of ibrutinib-associated central nervous system hemorrhage with platelet transfusion support (English)

1 reference

19 October 2017

1 reference

Karen Seiter

1

1 reference

19 October 2017

Michael F Stiefel

2

1 reference

19 October 2017

Jacqueline Barrientos

3

1 reference

19 October 2017

Azfar Shaikh

4

1 reference

19 October 2017

Nasir Ahmed

5

1 reference

19 October 2017

Paul Baskind

6

1 reference

19 October 2017

Delong Liu

7

1 reference

19 October 2017

4 July 2016

1 reference

19 October 2017

Stem cell investigation

1 reference

19 October 2017

3

1 reference

19 October 2017

27

1 reference

Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.

19 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Ibrutinib in previously treated Waldenström's macroglobulinemia.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4981699

17 August 2018

Identifiers

DOI

10.21037/SCI.2016.06.08

1 reference

19 October 2017

1 reference

19 October 2017

PubMed publication ID

27583253

1 reference